Stocktoria
Pacira BioSciences, Inc. PCRX
Pacira BioSciences, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $726.4M | $701.0M | $675.0M | $666.8M | $541.5M | $429.6M | $421.0M | $337.3M | $286.6M | $276.4M |
| R&D expense | $117.3M | $81.6M | $76.3M | $84.8M | $55.5M | $59.4M | $72.1M | $55.7M | $57.3M | $45.7M |
| SG&A expense | $368.8M | $294.1M | $269.4M | $254.5M | $199.3M | $193.5M | $200.8M | $177.3M | $161.5M | $152.6M |
| Operating income | $19.2M | -$73.4M | $87.7M | $60.0M | $89.9M | $46.4M | $10.5M | $15.9M | -$24.9M | -$32.0M |
| Interest expense | — | — | $20.3M | $40.0M | $31.8M | $25.7M | $23.6M | $21.9M | $18.0M | $7.1M |
| Income tax | $9.8M | $36.5M | $19.7M | -$2.6M | $14.4M | -$125.4M | $268,000 | $46,000 | $140,000 | $105,000 |
| Net income | $7.0M | -$99.6M | $42.0M | $15.9M | $42.0M | $145.5M | -$11.0M | -$471,000 | -$42.6M | -$37.9M |
| EPS (diluted) | $0.16 | $-2.15 | $0.89 | $0.34 | $0.92 | $3.33 | $-0.27 | $-0.01 | $-1.07 | $-1.02 |
| Operating cash flow | $152.0M | $189.4M | $154.6M | $145.3M | $125.7M | $77.0M | $70.5M | $48.9M | $17.8M | $33.5M |
| Free cash flow | $136.7M | $178.8M | $139.5M | $115.2M | $79.9M | $39.2M | $60.4M | $34.4M | -$1.5M | $8.7M |
| Cash & equivalents | $158.5M | $276.8M | $153.3M | $104.1M | $585.6M | $100.0M | $78.2M | $132.5M | $54.1M | $35.9M |
| Inventory | $152.9M | $125.3M | $104.4M | $96.1M | $98.5M | $64.7M | $58.3M | $48.6M | $41.4M | $31.3M |
| Total assets | $1.3B | $1.6B | $1.6B | $1.7B | $2.1B | $1.3B | $831.1M | $689.4M | $628.4M | $391.5M |
| Total liabilities | $571.8M | $775.2M | $704.3M | $906.2M | $1.3B | $654.8M | $476.1M | $368.1M | $348.9M | $172.5M |
| Shareholders' equity | $693.1M | $778.3M | $870.1M | $775.0M | $730.4M | $619.7M | $354.9M | $321.2M | $279.5M | $219.0M |
Growth · year-over-year · Revenue CAGR 11.3%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +3.6% | +3.9% | +1.2% | +23.1% | +26.0% | +2.0% | +24.8% | +17.7% | +3.7% | +11.0% |
| Net income growth | — | -337.3% | +163.7% | -62.1% | -71.2% | — | — | — | — | -2144.7% |
| EPS growth | — | -341.6% | +161.8% | -63.0% | -72.4% | — | — | — | — | -2650.0% |
| Free cash flow growth | -23.5% | +28.1% | +21.1% | +44.3% | +103.5% | -35.0% | +75.7% | — | -116.9% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.